Podcast Episodes
Back to Search
Invivyd develops monoclonal antibodies to prevent or treat infectious diseases. This approach could be useful in tamping down the measles outbreaks that have been occurring due to under-vaccination
CSO Robert Allen describes Invivyd's approach and why antibodies can be a good approach, especially as it relates to being resistant to viral evoluti…
4 months, 3 weeks ago
Bay Area based Epia Neuro exited stealth earlier this month with the goal of developing a device implanted in the skull that could act as an interface to a glove to helps stroke survivors regain grip
Co-Founder & CEO Michel Maharbiz describes the idea behind this brain-computer interface (BCI), which is not yet in human trials. While cautioning th…
4 months, 3 weeks ago
Peter Hotez discusses tropical disease, the importance of science communication, career advice for young scientists, and more
He describes his work in tropical disease, and how climate change has been elevating it in areas like the Gulf Coast of the United States. Plus, the …
4 months, 3 weeks ago
Physican and Biotech Investor Adam May reacts to this morning's 52 week Rezpeg data in alopecia from Nektar
He shares his thoughts on the data, the competitive profile of this IL-2 Treg therapy vs JAK inhibitors, and how the overall platform looks for other…
4 months, 3 weeks ago
10x Genomics today is announcing Atera, its new in situ spatial transcriptomics platform
Co-Founder and CEO Serge Saxonov walks us through the platform, which can process up to 800 whole-transcriptome samples per year (1 cm² each) on a si…
4 months, 4 weeks ago
Is this analyst the world's biggest bear on the weight loss space? After downgrading Lilly to a sell rating, HSBC's Rajesh Kumar discusses why he thinks pricing factors are being under-appreciated
Plus, discussions on key trial readouts outside of obesity: eplontersen, Lp(a), oral IL-23, and milvexian.
4 months, 4 weeks ago
Raymond James Biotech Innovation Symposium: Biotech analyst Tiago Fauth shares his read on the mood of investors and discusses companies he covers
He discusses Praxis, Insmed, Ionis, PTC Therapeutics, Rapport, and United Therapeutics.
5 months ago
Raymond James Biotech Innovation Symposium: Korro Bio CEO Ram Aiyer discussed how the company has chosen new RNA editing programs to move forward with this year
After experiencing a setback last year with Korro's LNP delivered alpha-1 antitrypsin deficiency program, he describes learnings from that experience…
5 months ago
Raymond James Biotech Innovation Symposium: Dyne's CEO John Cox shares an overview of the company's recent landmark DMD data
He describes both the biomarker and functional benefits seen in the December data for the company's next-generation exon 51 skipping therapy.
5 months ago
Raymond James Biotech Innovation Summit: Checking in with Vera's Founder & CEO Marshall Fordyce ahead of the July 7 FDA decision date for the APRIL & BAFF targeting IgAN treatment Atacicept
He reminds us of the unmet need for this type of therapy and discusses the planning that Vera has been doing ahead of the decision date.
5 months ago